Comparison of atazanavir/ritonavir and darunavir/ritonavir based antiretroviral therapy for antiretroviral naïve patients.

PubWeight™: 0.75^‹?›

🔗 View Article (PMID 28399819)

Published in BMC Infect Dis on April 11, 2017

Authors

Tony Antoniou¹^,2^,3, Leah Szadkowski⁴, Sharon Walmsley⁵^,4, Curtis Cooper⁶, Ann N Burchell⁷^,8^,5, Ahmed M Bayoumi⁷^,5, Julio S G Montaner⁹^,10, Mona Loutfy⁵^,11^,12, Marina B Klein¹³, Nima Machouf¹⁴, Christos Tsoukas¹³, Alexander Wong¹⁵, Robert S Hogg⁹^,16, Janet Raboud⁵^,4, Canadian Observational Cohort (CANOC) collaboration

Author Affiliations

1: Keenan Research Centre, Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, ON, Canada. tantoniou@smh.ca.
2: Department of Family and Community Medicine, St. Michael's Hospital, Toronto, ON, Canada. tantoniou@smh.ca.
3: University of Toronto, 410 Sherbourne Street, Toronto, ON, ON M4X 1K2, Canada. tantoniou@smh.ca.
4: Toronto General Research Institute, University Health Network, Toronto, ON, Canada.
5: University of Toronto, 410 Sherbourne Street, Toronto, ON, ON M4X 1K2, Canada.
6: The Ottawa Hospital Research Institute, University of Ottawa, Ottawa, ON, Canada.
7: Keenan Research Centre, Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, ON, Canada.
8: Department of Family and Community Medicine, St. Michael's Hospital, Toronto, ON, Canada.
9: British Columbia Centre for Excellence in HIV/AIDS, St. Paul's Hospital, Vancouver, BC, Canada.
10: University of British Columbia, Vancouver, BC, Canada.
11: Women's College Hospital Research Institute, Toronto, ON, Canada.
12: Maple Leaf Medical Clinic, Toronto, ON, Canada.
13: McGill University Health Centre, McGill University, Montreal, Quebec, Canada.
14: Clinique Médicale l'Actuel, Montreal, Quebec, Canada.
15: Regina Qu'Appelle Health Region, Regina, SK, Canada.
16: Simon Fraser University, Burnaby, BC, Canada.

Articles cited by this ↗

Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial. Ann Intern Med (2014) 3.48

Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study. J Acquir Immune Defic Syndr (2010) 2.64

Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients. J Antimicrob Chemother (2003) 1.76

Forgiveness of non-adherence to HIV-1 antiretroviral therapy. J Antimicrob Chemother (2008) 1.70

Metabolic effects of darunavir/ritonavir versus atazanavir/ritonavir in treatment-naive, HIV type 1-infected subjects over 48 weeks. AIDS Res Hum Retroviruses (2012) 1.35

Final 192-week efficacy and safety of once-daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infected treatment-naïve patients in the ARTEMIS trial. HIV Med (2012) 1.30

Cohort profile: the Canadian Observational Cohort collaboration. Int J Epidemiol (2010) 1.27

Ritonavir-boosted darunavir is rarely associated with nephrolithiasis compared with ritonavir-boosted atazanavir in HIV-infected patients. PLoS One (2013) 0.98

Comparative effectiveness of initial antiretroviral therapy regimens: ACTG 5095 and 5142 clinical trials relative to ART-CC cohort study. J Acquir Immune Defic Syndr (2011) 0.97

Comparative Effectiveness of First Antiretroviral Regimens in Clinical Practice Using a Causal Approach. Medicine (Baltimore) (2015) 0.82

Missing covariates in competing risks analysis. Biostatistics (2016) 0.81

Comparative incidence and health care costs of medically attended adverse effects among U.S. Medicaid HIV patients on atazanavir- or darunavir-based antiretroviral therapy. Value Health (2013) 0.78

Articles by these authors ⇆

Clinical impact of altered T-cell homeostasis in treated HIV patients enrolled in a large observational cohort. AIDS (2013) 0.79

Impact of the Data Collection on Adverse Events of Anti-HIV Drugs cohort study on abacavir prescription among treatment-naive, HIV-infected patients in Canada. J Int Assoc Provid AIDS Care (2013) 0.78

Factors associated with the frequency of monitoring of liver enzymes, renal function and lipid laboratory markers among individuals initiating combination antiretroviral therapy: a cohort study. BMC Infect Dis (2015) 0.75

Disparities in direct acting antivirals uptake in HIV-hepatitis C co-infected populations in Canada. J Int AIDS Soc (2017) 0.75